Nexien BioPharma Inc (PK) (NXEN) Quote

Check out Nugn and GDVM they have great possibilities.

It’s insanity after years of inactivity they do nothing

I think at this point their most valuable asset is being a public traded company in the OTCQB and should find a company of any kind with revenue and do a reverse merger. It's not ideal but would create some sort of liquidity for shareholders.

Looks like Evan picked up 4m shares.
Of what exactly?
No news from company in years.

Who is trading this stock everyday ?

What a POS with brain dead idiots running nothing - SELL THE SHELL !!!!!

Sell the shell and move on my god. What they think they are worth and what they're worth are two different things!

SOS anybody running this shit show

Sell the steaming POS of a company that has done nothing for years. How dumb are these morons.

Is Greenburg brain dead? He runs a public company that literally has done nothing in years. Just sell this POS as a shell

Diluting POS turd with no business

Sell the shell and end this turd

I only saw that shares were awarded to managers. No open market buys disclosed

Insiders all buying now

Sell this POS you brain dead retards. Shell is worth more then this zombie co.

10-k filed for period end 06/30/2022. https://www.otcmarkets.com/filing/html?id=16103240&guid=XIX-kH08gRLSJth

Lol they painted it down 500 shares
Zombie ticker

Dump away losers

Whoops! Very sorry!!!!

wrong company

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
First IND for NexImmune’s AIM nanoparticle platform in solid tumors
IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors. NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.

Kristi Jones, NexImmune’s CEO, commented, “The FDA clearance of our third IND marks another significant milestone for NexImmune and demonstrates our team’s continued focus and commitment to bringing novel therapies to patients with significant unmet need. NEXI-003 is our third T cell therapy and first candidate to address solid tumors. NEXI-003 consists of T cell populations simultaneously directed against multiple HPV tumor-relevant antigen targets. The T cells in our product candidate will consist of T cell subtypes critical to both potential anti-tumor activity and a phenotype intended to produce long-term immunologic memory required for durable responses.”

The Phase 1 trial will enroll patients at multiple clinical sites across the United States. The proposed study is a two-part, multicenter, open-label, dose-finding, first-in-human (FIH) study to characterize the safety and clinical activity of NexImmune’s HPV tumor-relevant antigen-specific CD8+ T cell product candidate (NEXI-003) in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers (with confirmed histopathology detection of HPV-16 and/or HPV-18 expression), who have received at least 1 prior regimen of standard therapy according to local standard of care guidance(s). The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24 to 36 patients overall, depending on the number of dose escalations. All patients will be followed for at least one year. Following initial data and after the recommended Phase 2 dose has been confirmed, NexImmune plans to expand the NEXI-003 development program to include other HPV related malignancies and evaluate potential SOC combination options across the patient populations.

About HPV-Related Cancers

Human papillomavirus (HPV)-related cancers are common epithelial malignancies that account for approximately 5% of all cancers globally. These cancers cause an estimated 12,500 deaths each year in the United States and more than 300,000 deaths each year throughout the world. Histologically, this family of cancers consists of squamous cell carcinomas and adenocarcinomas that occur in various anatomical sites including the oropharynx, uterine cervix, anus, vagina, vulva and penis. The high-risk HPV subtypes are most commonly HPV-16 and HPV-18. Malignant transformation results through the activation of the expression of the E6 and E7 HPV oncogenes, which inhibit the tumor suppressors p53 and Rb. These oncoproteins also inhibit apoptosis of tumor cells, deregulate the cell cycle, result in the accumulation of genetic instability, promote angiogenesis and facilitate the invasiveness and metastatic spread of cancerous cells.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least three prior lines of therapy, respective

Brain dead management

Very long term

Been a long wait

Hopefully another patent

They are overdue to make some announcement..

There it is flushed down the toilet POS

Stranger still seeing buyers with details about continuing research

S.253 - Cannabidiol and Marihuana Research Expansion Act

https://www.congress.gov/bill/117th-congress/senate-bill/253/text

This one was passed by the Senate and has more GOP support than Nadler's MORE Act that passed the House.

Yes, looks like we are starting to get some eyes on us. I would think we will hear that we are moving into a preclinical study fairly soon. Good results from that would bring in some big funding for the next level.

Nice find! This one is worth the long hold :)

NXEN mentioned alongside GWPH. It Seems things are starting to move.

https://www.advancemarketanalytics.com/reports/157542-global-cannabinoid-drugs-market

one more shake and we could see .25

Crazy thin L2

They could be shaking out the trees here... it has been a long time.
Something may be popping soon.. The SS is awesome.. I guess that is why we have been here for years.

Agree this is behind the action and hopefully we will get an announcement on the UPENN research.

Just days after the Senate passed a cannabis research bill, the House of Representatives has passed its own. Both bills aim to streamline, and, by extension, expand, cannabis research, but the two bills have some noteworthy differences.
https://cannabiswire.com/2022/04/04/cannabis-research-bills-advance-in-congress/

I guess the next couple days will reveal if today was a fluke?

Wow! What the heck happened here today? Big news on the horizon.

$NXEN WOW crazy thin

Very interesting... hmmm.. something is up..

hmmm

Maybe this will turn into a Disney movie with a happy ending

Can’t believe how portly this company is run.

We will see where this news leads us, I haven’t researched This guy yet.




9:00a ET 2/3/2022 - Globe Newswire
Nexien BioPharma Engages Dr. Benedikt Schoser as Advisor
Mentioned: NXEN
Nexien BioPharma Inc. (OTCQB: NXEN) ("Nexien" or the "Company") today announced that it has retained Dr. Benedikt Schoser as an advisor to the Company. Dr. Schoser, who has previously served as a scientific advisor to the Company, is senior consultant at the Friedrich-Baur Institute, Department of Neurology at the Ludwig-Maximilians-University of Munich, Germany's major national referral center for rare neuromuscular diseases, and is considered one of the world's top researchers in myotonia and the treatment of myotonic dystrophy. The Company also retained regulatory counsel and is initiating discussions with a pharmaceutical company to pursue formulation development. Richard Greenberg, Nexien's CEO and Chairman of the Board, stated, "We are excited to be establishing a team to address myotonic dystrophy and myotonia. The successful completion of our recent financing enables us to recommence our myotonic dystrophy research." Greenberg added, "Nexien has already been granted a United States patent for the treatment of dystrophies and myotonia and looks forward to benefiting from the team's knowledge regarding myotonic dystrophy, while seeking to advance a drug development strategy to treat myotonic dystrophy and myotonia."

Morons put out an 8K with convertible notes and do NOT announce a business plan. Is their plan to sell shares like other OTC garbage tickers?

Hopefully- we’ll see

Looks like we are back In business. Up to $1 million possibly. I do know they’ve wanted to get that initial money to kick something off in Germany so hopefully the pieces come together.

Dumpster play - great shell to sell

Spec play?